GlobeNewswire: International Stem Cell Corporation Contains the last 10 of 170 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:12:22ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/05/17/1826864/0/en/International-Stem-Cell-Corporation-Announces-Operating-Results-for-the-Quarter-Ended-March-31-2019.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 20192019-05-17T12:30:00Z<![CDATA[CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update announcing operating results for the three months ended March 31, 2019.]]>https://www.globenewswire.com/news-release/2019/05/08/1819371/0/en/International-Stem-Cell-Corporation-is-Valued-at-43-Million-Market-Value-by-Edison-Investment-Research.html?f=22&fvtc=4&fvtv=29249 International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research2019-05-08T12:30:00Z<![CDATA[CARLSBAD, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $43 million, up from $42 million in December 2018, by Edison Investment Research ("Edison")*, a world-renowned investment intelligence firm with more than one hundred analysts, investment experts, and roadshow professionals, with offices in North America, Europe, the Middle East and Asia. The research report is available on Edison's website and can be accessed here. The report features an analysis of ISCO's financial data, along with an investment summary that showcases the Company's cell therapy for Parkinson's disease and traumatic brain injury as key industry differentiators. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com. To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell *The Edison report was sponsored by the Company. Safe harbor statement Statements pertaining to anticipated developments, expected pre-clinical studies (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements. Contacts International Stem Cell Corporation Russell Kern, PhD Executive Vice President, Chief Scientific Officer ir@intlstemcell.com Joe Green Investor Relations Edison Inc. jgreen@edisongroup.com +1 (646) 653-7030]]>https://www.globenewswire.com/news-release/2019/04/29/1811265/0/en/International-Stem-Cell-Corporation-Completes-Enrollment-and-Dosing-in-its-Parkinson-s-Disease-Clinical-Trial.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial2019-04-29T12:30:00Z<![CDATA[CARLSBAD, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject enrollment in its phase 1 clinical trial of ISC-hpNSC® for the treatment of Parkinson’s disease. The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC® cells. This clinical trial, which involved 12 patients with Parkinson’s disease, was conducted in collaboration with investigators from Royal Melbourne Hospital, a leading medical institution with an international reputation for excellence.]]>https://www.globenewswire.com/news-release/2019/04/15/1803964/0/en/International-Stem-Cell-Corporation-Announces-2018-Fourth-Quarter-and-Year-End-Results.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results2019-04-15T12:30:00Z<![CDATA[CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced fourth quarter and year-end financial results for the period ending on December 31, 2018 and provided a business update.]]>https://www.globenewswire.com/news-release/2019/03/04/1745843/0/en/International-Stem-Cell-Corporation-Commences-Trading-on-the-OTCQX-Best-Market.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Commences Trading on the OTCQX Best Market2019-03-04T12:00:00Z<![CDATA[CARLSBAD, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been approved to trade on the OTCQX Best Market in the United States. International Stem Cell Corporation upgraded to the OTCQX from the OTCQB Venture Market.]]>https://www.globenewswire.com/news-release/2019/02/13/1724660/0/en/International-Stem-Cell-Corporation-Publishes-Successful-Results-in-Traumatic-Brain-Injury.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury2019-02-13T13:30:00Z<![CDATA[CARLSBAD, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the results of the Company’s preclinical studies in traumatic brain injury (TBI) have been published in Theranostics, a prestigious peer-reviewed medical journal. The publication, titled, “Human parthenogenetic neural stem cell grafts promote multiple regenerative processes in a traumatic brain injury model,” demonstrated that the clinical-grade neural stem cells used in our Parkinson’s disease clinical trial, ISC-hpNSC®, significantly improve TBI-associated motor, neurological, and cognitive deficits without any safety issues. The paper is available on the Company’s website.]]>https://www.globenewswire.com/news-release/2019/01/15/1691685/0/en/International-Stem-Cell-Corporation-Granted-Key-US-Patent-Protecting-Anti-Aging-Business.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business2019-01-15T13:30:00Z<![CDATA[CARLSBAD, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based, clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company US Patent No. 10,172,890 on the topical use of lysate from human parthenogenetic (non-embryonic) stem cells to visibly improve signs of skin aging. The patented stem cell lysate is encapsulated and delivered from protective liposomes, and is combined with antioxidants, vitamins and peptides to provide skin benefits including reducing the depth/number of facial fine lines and wrinkles, increasing skin elasticity/firmness, and improving skin hydration. This proven to be effective technology used in the products was developed by key ISCO scientists, who brought neural stem cells to the clinical trial for the treatment of Parkinson’s disease.]]>https://www.globenewswire.com/news-release/2018/11/15/1652275/0/en/International-Stem-Cell-Corporation-Announces-Strong-Financial-Results-for-the-Three-and-Nine-Months-ended-September-30-2018.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 20182018-11-15T13:30:00Z<![CDATA[CARLSBAD, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2018.]]>https://www.globenewswire.com/news-release/2018/11/05/1645106/0/en/International-Stem-Cell-Corporation-Announces-Positive-Top-Line-Preliminary-Results-from-Parkinson-s-Disease-Clinical-Trial.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial2018-11-05T13:30:00Z<![CDATA[CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today positive 12-month results of the first cohort and six-month interim results of the second cohort of its currently-ongoing, single-arm, open-label phase 1 clinical study (NCT02452723) evaluating the safety and tolerability of its lead candidate, ISC-hpNSC®, a cellular therapeutic consisting of human parthenogenetic neural stem cells, for the treatment of Parkinson’s disease (PD).]]>https://www.globenewswire.com/news-release/2018/11/05/1645107/0/en/International-Stem-Cell-Corporation-Announces-Positive-Top-Line-Preliminary-Results-from-Parkinson-s-Disease-Clinical-Trial.html?f=22&fvtc=4&fvtv=29249International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial2018-11-05T13:30:00Z<![CDATA[CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today positive 12-month results of the first cohort and six-month interim results of the second cohort of its currently-ongoing, single-arm, open-label phase 1 clinical study (NCT02452723) evaluating the safety and tolerability of its lead candidate, ISC-hpNSC®, a cellular therapeutic consisting of human parthenogenetic neural stem cells, for the treatment of Parkinson’s disease (PD).]]>